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Aim: The purpose of the present study was to distinguish the effects of both diabetes
mellitus type 2 (DM2) and diabetic polyneuropathy (DPN) on mobility, muscle strength
and health related quality of life (HR-QoL).
Methods: DPN patients (n = 98), DM2 patients without DPN (DC) (n = 39) and healthy subjects
(HC) (n = 19) performed isometric and isokinetic lower limb muscle strength tests. Mobility
was determined by a timed up and go test (TUGT), a 6 min walk test and the physical activity
scale for the elderly questionnaire. HR-QoL was determined by the SF36 questionnaire.
Results: DPN patients had moderate polyneuropathy. In both DPN and DC patients leg
muscle strength was reduced by 30–50% compared to HC. Muscle strength was correlated
with mobility tests, and reduced muscle strength as well as impaired mobility were associ-
ated with a loss of HR-Qol (all p < 0.05). We did not observe major differences in muscle
strength, mobility (except for the TUGT, p < 0.01) and HR-QoL between diabetic patients with
and without DPN.
Conclusion: DM2 patients, with and without DPN, have decreased maximal muscle strength
in the lower limbs and impaired mobility. These abnormalities are associated with a loss of
HR-QoL. The additional effect of moderate DPN was small in our patients.
# 2011 Elsevier Ireland Ltd. 
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Diabetes type 2 (DM2) is accompanied by a wide range of
impairments and several studies have shown that DM2 is
associated with a loss of mobility [1–4]. This limited mobility
encloses a broad range of daily activities. Limited mobility can
have a large impact on the independence of an individual once
basic daily activities such as rising from a chair, walking stairs
and doing groceries are impaired. Reduced muscle strength* Corresponding author at: Department of Movement Sciences, Maastri
Tel.: +31 43 3881392; fax: +31 43 3670972.
E-mail addresses: Herman.IJzerman@maastrichtuniversity.nl, herm
0168-8227# 2011 Elsevier Ireland Ltd. 
doi:10.1016/j.diabres.2011.10.026
Open access under the Elsevier OA licensecould be an important factor in this mobility loss and
Andersen et al. [5] showed in an earlier study that DM2 is
associated with loss of muscle strength around the ankle and
knee joint. The loss of mobility and muscle strength of the
lower extremities can enhance each other. Inactivity will lead
to loss of muscle mass, resulting in decreased muscle strength
and vice versa increased muscle weakness will lead to an
increased effort to be physical active. This will result in a
negative spiral of become less active, losing muscle strength,cht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
anijzerman@hotmail.com (T.H. IJzerman).
.
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QoL) [6].
Several factors could be responsible for the limited mobility
and decreased muscle strength in diabetic patients such as
intrinsic abnormalities in diabetic muscle, impaired capillary
recruitment, peripheral arterial disease and diabetic poly-
neuropathy (DPN) [5,7,8]. DPN occurs in approximately 20–40%
of all diabetic patients [9,10]. Furthermore, neuropathy has
been associated with impaired mobility, loss of muscle
strength and decreased HR-QoL, as reviewed elsewhere [7].
Earlier studies found that patients with severe DPN have
increased muscle weakness in lower extremities [5,11].
However, several studies have shown that diabetic patients
without DPN also have decreased muscle strength and volume
compared to healthy subjects [5,12,13]. The contribution of
polyneuropathy to the limited mobility and reduced and
reduced muscle strength is therefore still matter for debate.
In a recent accelerometer study we found that DPN and
handgrip strength were each independently associated with
an approximately 30% reduction in the daily number of steps/
day during a 1 week period [14]. However, the role of impaired
lower extremity muscle strength in the loss of mobility and
QoL in DM2 patients with and without DPN remains unclear.
Therefore, the aim of this study was to determine the effect of
the diabetic state per se and of DPN on lower extremity muscle
function, mobility and health-related QoL (HR-Qol). Further-
more, the relations between these primary outcome param-
eters were assessed.
2. Materials and methods
2.1. Subjects
Patients with DM2 (DC group) and DPN (DPN group) were
recruited in one university and four district hospitals in the
south of the Netherlands. Healthy subjects (HC group) were
recruited from a database that contained healthy volunteers
who participated in earlier studies. All subjects were at least 50
years and were excluded if diagnosed with severe cardiac
disease, renal insufficiency (creatinin > 180 mmol/L), intermit-
tent claudication, muscular disorders or rheumatoid arthritis.
In addition, DM2 patients were excluded if they had been
diagnosed with foot ulcers in the last six months prior to the
study, or had nerve damage not due to DPN. Written informed
consent was obtained from all participants and the protocol
was approved by the medical ethical committee of the
Maastricht University Medical Centre+.
2.2. Clinical assessment of polyneuropathy
Peripheral polyneuropathy was diagnosed and classified
based on a standardised clinical neurological examination
(CNE) in which a CNE score 5 indicates the presence of
peripheral neuropathy and a score of 15 is considered as
severe DPN [15]. In short, the CNE score is determined by
examining the Achilles tendon reflex, vibration awareness,
sharp–blunt discrimination, touch sense, position sense of the
hallux and manual assessment of extensor muscle strength of
the hallux and flexor muscle strength of the foot in which allitems are scored as either normal, impaired or absent (0–2
points). In addition, the scoring of light touch sense was
related to the anatomical level below which it is impaired (toe,
mid-foot, ankle, mid-calf and knee) (0–5 points). In an earlier
study of our group, were a sub population of the current
population was studied, EMG and CNE score resulted in the
same diagnosis of DPN in our DM2 patients [16].
2.3. Isometric and isokinetic muscle strength
Two dynamometers, the Cybex II (CMSI, Stoughton, MA) and
the Biodex System 3 (Biodex Medical Systems, New York),
were used to determine isometric and isokinetic muscle
strength of dorsal and plantar flexor muscles of the ankle joint
and the extensor and flexor muscles of the knee joint. Both
systems are frequently used in scientific studies and both
dynamometers are validated systems. According Gosker et al.
[17] both systems yield similar results. Half of all subjects were
tested on the Biodex and half on the Cybex.
2.4. Isometric test
To determine maximal, voluntary ankle joint moments,
participants were positioned in a 908 hip and knee flexion.
The subject’s ankle joint centre was aligned with the rotation
centre of the dynamometer. The dorsal and plantar ankle joint
moments were determined at four different angles; 808, 908,
1058 and 1208, where 808 equals maximal dorsal flexion and
1208 compares maximal plantar flexion. One single maximal
voluntary contraction was maintained approximately 3 s.
Between subsequent contractions subjects were allowed
2 min of rest. Passive ankle joint moments were measured
one second before the contraction. This passive moment
resulted from the weight of the foot, the tension of passive
structures and the weight of the arm of the dynamometer.
Depending on the joint angle, the passive moment could be in
dorsal or plantar flexion direction. The recorded maximal
moments were corrected for these passive moments. A similar
protocol was used to determine maximal voluntary muscle
strength for the knee joint flexors and extensors. Subjects
were positioned in a 908 hip flexion. Maximal voluntary knee
joint moments were assessed at five angles: 308, 508, 708, 908
and 1008, where 08 represented a fully extended leg. All
measurements were performed in the right leg.
Maximal strength was determined by fitting a second
degree polynomial function to the joint moment data at
subsequent joint angles. The highest value of this fitted
polynomial was considered the maximal strength. All joint
moments were normalized for body mass [16].
2.5. Isokinetic test
The subjects were positioned the same as during the isometric
tests. The participants were asked to push and pull as hard and
fast as possible over their maximal range of motion with
verbal encouragement of the researcher. The joint angular
velocity was set on 1208/s. Subjects performed 20 repetitions.
The work of each of these plantar and dorsal flexion
repetitions of the ankle and extension and flexion repetitions
of the knee was calculated and expressed as Nm/kg. To
Table 1 – Demographic, neurological and blood para-
meters.
DPN DC HC P-value
N 98 39 19
Sex
(male/
female)
80/18b 20/19 15/4b 0.001
Age (yr) 67  8 62  7a 68  5 0.002
Height (m) 1.74  0.08b 1.68  0.10 1.72  0.07 0.002
Weight (kg) 94  18a 88  15a 73  8 <0.001
BMI (kg m2) 30.8  5.0a 31.2  5.7a 24.4  1.9 <0.001
CNE score 13  5a,b 3  2 1  2 <0.001
HbA1c (%) 7.3  1.1a 7.1  1.0a 6.0  0.5 <0.001
Glucose
(mmol/L)
8.5  2.3a 8.0  2.2a 5.6  0.6 <0.001
Creatinine
(mmol/L)
98  30b 81  22 89  12 0.004
CNE = clinical neurological examination; P-value: main effect of
the analysis of variance between the three groups.
a Post hoc analysis p  0.05 compared to HC.
b Post hoc analysis p  0.05 compared to DC.
Fig. 1 – Normalized maximal isometric muscle strength of
the plantar flexors (MaxPlant), dorsal flexors (MaxDors),
knee extensors (MaxExt) and knee flexors (MaxFlex) (P-
value: main effect of the analysis of variance between the
three groups. Post hoc analysis p = 0.001 compared to HC.
Joint moments were normalized for body mass MaxPlant.
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adapted formula of Moreau et al. was used [18]. For ankle
dorsal and plantar flexion and for knee extension and flexion,
the fatigue index (FI) was calculated as the ratio of the mean
work of the 16th till 20th repetition over the mean work of the
highest, five consecutive repetitions within the first eight
repetitions. A FI approaching 100% indicates that work decline
during the test is low. Results of muscle fatiguability were
considered as missing if the highest consecutive five repeti-
tions were not performed within the first eight repetitions.
2.6. Mobility
Three validated tests were used to assess mobility. In the
6 min walk test (6 MWT) subjects were asked to walk as far as
possible within 6 min without running on a 220 m flat track; in
the timed up and go test (TUGT) subjects were asked to stand
up from a chair, walk three meters at comfortable speed, turn,
walk back and sit down again. The Physical Activity Scale of
the Elderly (PASE) questionnaire was used to determine the
daily activity pattern. The higher the score at the PASE
questionnaire the more active a subject is in daily life.
2.7. Quality of life
The SF36 questionnaire was used to determine HR-QoL. This
questionnaire contains 36 items. It measures health on nine
multi item dimensions, based on functional status, well being
and overall evaluation of health [19]. The higher the score at
the SF36, the more positive a subject was about experienced
HR-QoL.
2.8. Biochemical analysis
Overnight fasting blood samples were drawn for measure-
ment of glucose, glycated hemoglobin (HbA1c) and creatinine.
2.9. Statistical analysis
Results are presented as mean  standard deviation. Analysis
of variance was performed to detect differences between the
three experimental groups. We used analysis of covariance to
test differences between groups in the muscle strength,
mobility and QoL data; age and gender were entered as
covariates. If main effects were significant, the Bonferroni test
was used for post hoc analysis. Pearson’s correlation coeffi-
cients were calculated between muscle function (muscle
strength and fatiguability), the three mobility tests and the
nine QoL items. Within the group of DPN patients, correlations
between the level of nerve damage (CNE score) and maximal
muscle strength, mobility and QoL were evaluated. A p-value
of <0.05 was considered as significant.
3. Results
We included 98 DM2 participants with DPN, 39 DM2 patients
without DPN and 19 healthy control subjects. Demographic,
neurological and blood parameters are presented in Table 1. In
general, we included elderly obese diabetic subjects with goodto moderate blood glucose control. The DC group was 5 years
younger than the HC group ( p < 0.01). Height and creatinine
were higher in the DPN group than the DC group ( p < 0.01),
whereas weight, BMI, HbA1c and glucose were higher in both
diabetic groups ( p < 0.001) compared to the HC group. By
definition, the CNE score was higher ( p < 0.001) in patients
with DPN compared to both other groups.
3.1. Muscle strength and relative fatigue
Both DPN and DC groups had diminished, maximal, voluntary
muscle strength in all parameters measured around the knee
and ankle joints compared to the HC group (reductions of 34–
47%), whereas no differences were observed between the DPN
and DC groups (Fig. 1). Although all FI’s were numerically
lower in both diabetic groups compared to the HC group
( p > 0.1), this was not statistically significant except for the
fatiguability of the knee joint flexors. This muscle group had in
Table 2 – Muscle strength, mobility and QoL parameters.
DPN DC HC P-value
FatiguePlant (%) 61  20 57  14 65  14 0.315
FatigueDors (%) 42  16 39  14 47  14 0.226
FatigueExt (%) 63  13 66  13 70  8 0.159
FatigueFlex (%) 71  10 70  11a 78  9 0.039
PASE 141  81 151  91 195  72 0.06
6 MWT (m) 477  89a 486  87a 668  68 <0.001
TUGT (s) 9.3  2.8a 8.4  2.4 7.2  0.9 0.002
SF36 Physical functioning 68  25a 71  28a 91  11 0.001
SF36 Social functioning 77  23a 75  28a 93  15 0.02
SF36 Role limitations (physical problems) 66  39a 62  44a 97  8 0.003
SF36 Role limitations (emotional problems) 78  36 66  44 91  27 0.051
SF36 Mental heatlh 74  20 71  17a 85  15 0.032
SF36 Vitality 61  18a 60  20a 79  20 <0.001
SF36 Pain 71  24a 68  28a 91  11 0.003
SF36 General health perception 50  20a 50  19a 77  15 <0.001
SF36 Health change 46  20 51  25 54  17 0.197
P-value: main effect of the analysis of variance between the three groups.
a Post hoc analysis p  0.05 compared to HC. Fatigue index of the plantar flexors (FatiguePlant), dorsal flexors (FatigueDors), knee extensors
(FatigueExt) and knee flexors (FatigueFlex).
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group (Table 2).
3.2. Mobility
Both diabetic groups showed a decreased mobility compared
to the HC group. During the 6 MWT, participants in both
diabetic groups walked significantly less far than HC partici-
pants (approximately 28%, Table 2). The 6 MWT distance for
DC and DPN did not differ. The PASE score showed a similar,
but no significant trend ( p = 0.06) with HC participants
reporting more daily physical activity than DC and DPN
subjects. During the TUGT the DPN group needed significantly
more time than HC group (an increase of 29%); no differences
were observed between the other groups.
3.3. Quality of life
In the DPN group six of the nine SF36 items and in the DC group
seven of the SF 36 items were significantly lower than in the
HC group (Table 2). No differences were observed in perceived
HR-QoL between both diabetic groups.
3.4. Correlations
Significant correlations were observed between all items of the
SF36 and muscle strength, except for health change and role
limitations related to emotional problems. The other seven
items had significant positive correlations ( p < 0.05) with dorsal
and plantar flexion as well as knee flexion and extension
maximal voluntary muscle strength. The correlation coeffi-
cients of these associations were between 0.19 and 0.41.
Similar results were found when the nine SF36 items were
correlated with the mobility tests, except for health change
and mental health. The other seven items were correlated
( p < 0.05) with the 6 MWT and the PASE questionnaire with
correlation coefficients between 0.20 and 0.59. The same seven
items of the SF36 questionnaire had negative correlations with
the TUGT (R between 0.29 and 0.46, p < 0.05).Finally, all muscle strength parameters were correlated
with the mobility parameters ( p < 0.05), with correlation
coefficients between 0.22 and 0.59.
No significant correlations were observed for the FI of the
ankle and dorsal flexors and knee extensors and flexors and
the QoL and mobility parameters.
The level of DPN (CNE score) had no significant influence on
the majority of parameters, except that a correlation was
observed between the severity of DPN and the TUGT (R = 0.28,
p < 0.05).
4. Discussion
The present study clearly demonstrated that DM2 is associat-
ed with a marked reduction in lower leg muscle strength, that
muscle strength was correlated with mobility and that loss of
both lower leg muscle strength and of mobility is associated
with a loss of HR-Qol in these elderly patients. We did not
observe in this study major differences in muscle strength,
mobility (except for the TUGT) and QoL between the diabetic
patients with and without DPN. One of the innovative aspects
of the current study was that we studied the triad leg muscle
strength, mobility and quality of life in the same patients.
Although there are numerous studies on abnormal muscle
metabolism and its role in the development of insulin
resistance, the number of studies on muscle strength and
its role in the development of impaired mobility and quality of
life in DM2 is limited. Based on the present results we could
conclude that DM2 has a major effect on maximal muscle
strength with reductions of approximately 30–50% in both the
upper and lower leg. Our findings are in line with previous
studies that reported loss of muscle strength in patients with
DM2, although the loss of muscle strength was in our study
larger than the studies reported earlier [5,11,14,20–22]. In the
Health ABC Study, elderly adults (mean age 74 years) with DM2
had a mean reduction of leg muscle strength of approximately
3% although muscle mass in their legs was greater than those
without diabetes. Muscle quality (strength corrected for
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[22]. We found a much larger reduction in muscle strength in
our patients, that may be (in part) related to differences in the
calculation of muscle strength. We corrected muscle strength
for body weight, while this was not done in the Health ABC
study [22]; if we recalculate the data of this latter study the
diabetic patients had a reduction in muscle strength of
approximately 10%, which is still less than in the present
study. Another explanation could be that our control subjects
were relative fit and had a higher muscle strength compared to
the control subjects in the Health ABC study [22]. Several
mechanisms, alone or in concert, could be responsible for the
loss of muscle strength in DM2. As lack of physical exercise is
one of the central mechanisms in the development of DM2,
inactivity and disuse probably contribute to the relative poor
muscle strength. Moreover, abnormal mitochondrial function,
abnormal free fatty acid metabolism and an inadequate rise in
microvascular blood supply during exercise [23,24] could
further impair muscle function. In the current study we did
not observe a relation between loss of nerve function and loss
of muscle strength, in contrast to earlier studies [5,12]. One of
the likely explanations is that the majority of our DPN patients
had relative mild DPN. In the studies of Andersen et al. [5] and
of Andreassen et al. [12] leg muscle weakness was in particular
observed in patients with severe, symptomatic, neuropathy
and not in patients with less severe DPN. These data suggest
that additional loss of muscle strength is a relatively late
phenomenon in the course of DPN and occurs at a severe stage
of the disease. These data suggest that additional loss of
muscle strength is a relatively late phenomenon in the course
of DPN and occurs at in patients with a more severe and more
advanced stage of disease than the patients included in the
current study.
Muscle fatiguability, determined with an isokinetic proto-
col, was somewhat increased in our diabetic patients, but
these differences were clearly less prominent than the decline
of maximal voluntary muscle strength, determined with an
isometric protocol. Oberbach et al. showed that patient with
DM2 have increased proportion of muscle fiber type 2 (fast
twitch fiber) and decreased proportion of muscle fiber type 1
(slow twitch and responsible for endurance capacity of a
muscle) [25]. Changes in fiber composition could therefore (in
part) explain the increased muscle fatiguability in patients
with DM2. In contrast, in type 1 diabetic patients Andersen [26]
observed, a significant higher FI of five percent in comparison
to healthy volunteers while lower leg muscle strength was
reduced, as in our type 2 patients. At this moment we cannot
give an explanation for this discrepancy between type 1 and
type 2 diabetic patients, but this might be related to underlying
insulin resistance and impaired metabolic flexibility in type 2
diabetes [27]. We could not find a relation between muscle
fatiguability and DPN, as also reported earlier [26]. However,
research in the field of muscle fatiguability in DM2 patients is
scarce and more (human) research is needed to gain a clear
insight into this phenomenon.
Muscle strength is one of the important determinants of
mobility in diabetic patients. In an earlier population based
study we observed that hand grip strength predicted the
number of steps taken during the day by patients with DM2
[14]. Our current data further extend this observation asreductions in muscle strengths in both the upper and lower leg
were associated with the marked loss of mobility in our
diabetic patients. As in our earlier study we did not observe a
major impact of DPN on the mobility tests we performed,
except the TUGT [14]. The TUGT was the most challenging
mobility test for our subjects and poor performance during
this test is probably (in part) related to the loss of propriocepsis
in our DPN patients. DPN is associated with several changes in
gait characteristics, such as reduced gait velocity, step length
and frequency and postural instability, which in part may be
related to loss of propriocepsis [28]; moreover in patients with
DPN the timing of muscle activation is altered during walking
as we recently observed [29]. In addition, although van Sloten
et al. [14] did not find significant associations between DPN
and functional mobility test in a laboratory setting, those DPN
patients were significantly less active in daily life with a
marked reduction in the number of steps/day when compared
to subjects without DPN. These data of van Sloten et al. were in
line with the conclusions of Allet et al. [28]; these authors
found that diabetic patients, and in particular DPN patients,
have deteriorated temporal and spatial gait parameters during
walking tests in challenging daily life situations.
These studies suggest that (moderate) DPN does not have a
large effect on the capability to be active, but more on mobility
behavior and on gait characteristics, in particular in a more
challenging environment. Future studies addressing the effect
of DPN on mobility should therefore focus more on mobility
and functional mobility tasks in daily life to determine the
impact of DPN on the actual mobility capability in diabetic
patients.
HR-QoL was decreased in our group of DM2 patients
compared to healthy persons as shown in several studies [30]
and the association between mobility and HR-QoL was
observed by other authors [4,31]. Diminished muscle strength
and mobility can result in infirmities and more dependence in
daily life with negative influence on HR-QoL. The significant
correlations between muscle strength, mobility and HR-QoL
parameters showed this association clearly. In addition, there
was no clear difference in HR-QoL between our DC and DPN
group, in contrast with other studies [7]. An explanation can be
found in the study Currie et al. [32], these authors concluded
that diminished QoL in DPN is associated with the level of pain
that is experienced. In the current study most patients had
painless DPN and we did not observe differences in pain
between the DC and DPN group.
Our study had some limitations. The mean age of the DC
group was significantly lower than in the HC group. This could
lead to an overestimation of the results of the DC subjects
compared to the HC group. To correct for this, age was entered
as a covariate in the statistical analysis. The results of the DC
group are comparable with the DPN group who had similar age
as the HC group. If there would have been an important age
effect, we would have expected the DC group to have higher
muscle strength, mobility and QoL than the DPN group. This
turned out not to be the case. In addition, the DC group
included relatively more female participants than both other
groups and therefore we used also gender as a covariate in our
statistical analysis.
In conclusion, in this study we demonstrated that DM2
patients have decreased maximal muscle strength of the
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extensors and flexors of the knee joint and that they suffer
from impaired mobility. These abnormalities are associated
with a loss of health related quality of life. The additional
effect of moderate DPN was small in our patients. Physical
exercise is one of the cornerstones in the prevention [33,34]
and treatment of diabetes; our data suggest that in the future
more emphasis could be placed on interventions to increase
leg muscle strength to improve mobility in patients with type 2
diabetes.
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